Radiation-Induced Leukemia Model Service

The radiation-induced leukemia model translates the carcinogenic legacy of ionizing radiation into an experimentally controlled system, most powerfully in the CBA/H mouse, where a single defined X-ray dose sets in motion a genetically choreographed leukemogenesis that mirrors human acute myeloid leukemia. Alfa Cytology operates this uniquely long-horizon platform end to end, from dosimetry-verified irradiation and lifetime follow-up of irradiated cohorts to bone marrow, spleen, and liver-based diagnosis and molecular confirmation of every case.

Overview of Radiation-Induced Leukemia Model

Ionizing radiation was among the first environmental agents recognized to cause cancer in humans, with acute myeloid leukemia the signature malignancy of exposed populations from atomic-bomb survivors to radiotherapy patients, and the CBA/H mouse stands as the definitive experimental system for dissecting that relationship. In this model, a single whole-body exposure of approximately 3 Gy delivered to 12-week-old male CBA/H animals reproducibly induces myeloid leukemia in roughly one in four animals, with a latency of 18 to 24 months and an essentially negligible spontaneous background of fewer than one case per thousand. The induced disease infiltrates sternal bone marrow, liver, and spleen, presents with morphology closely resembling the human malignancy, and carries a dose-response curve whose curvilinear shape, peaking near 3 Gy before declining at higher doses through hematopoietic cell killing, mirrors patterns documented in human epidemiology.

Fig 1. Working model of the radiation-induced AML model: wild-type CBA mice show ~15% AML incidence at ~15 months after irradiation with biallelic Spi1 mutation plus chromosome 2 deletion, whereas CBA^Spm/+ mice reach 100% incidence at ~7 months. (Brown, Natalie, et al., 2023)

The model's deepest contribution is molecular: radiation-induced AML in CBA/H follows a comprehensively characterized two-hit sequence in which an acute exposure first generates a hemizygous interstitial deletion of chromosome 2 that removes one copy of the hematopoietic transcription factor gene Sfpi1 (encoding PU.1), and affected bone marrow cells, carrying this lesion in 20–25% of irradiated mice from as early as 20 hours after exposure, persist as a dormant pre-leukemic pool for months before a second hit, typically an R235 point mutation in the remaining Sfpi1 allele, completes malignant transformation. This del2-plus-point-mutation architecture, together with cooperating events on chromosome 4 and Flt3-ITD alterations in a subset of tumors, has made CBA/H the reference strain for radiation protection research, for testing medical countermeasures against radiation carcinogenesis, and for validating the mechanistic extrapolations that inform human radiation risk assessment in vivo.

Principles of Radiation-Induced Leukemia Model Construction

The radiation leukemia model differs fundamentally from chemically induced systems: its carcinogen is energy rather than matter, its output is governed by dosimetry and radiation quality, and its latency is measured in years of animal life. The governing elements are tabulated below.

Our Services

With latencies stretching across a substantial fraction of a mouse's lifespan, the radiation leukemia model is unforgiving of lost animals and lost records, which is why Alfa Cytology anchors every engagement to dosimetry certificates, lifetime cohort tracking, and scheduled interim health monitoring that keeps 18-to-24-month studies fully auditable from exposure to diagnosis.

Workflow of Radiation-Induced Leukemia Model Construction

A radiation leukemia study is defined by a single exposure event followed by a year and a half of disciplined observation, with every diagnosis resting on standardized organ-based criteria. The operational sequence is as follows.

1. Study design and strain configuration: The sponsor's objectives determine strain, typically male CBA/H for mechanistic and countermeasure work, the radiation quality and dose, group sizes powered for incidence endpoints, and any mitigator or protector intervention arms.
2. Animal receipt and acclimatization: Twelve-week-old animals undergo a minimum one-week habituation with baseline body weights, general health status, and, where designs require, baseline blood counts recorded.
3. Randomization and cohort assignment: Animals are randomized across groups and individually identified, since lifetime follow-up demands unambiguous tracking of every irradiated and control animal for the duration of the study.
4. Dosimetry-verified irradiation: Animals receive the protocol whole-body exposure in a calibrated irradiator, with delivered dose confirmed against a certified dosimetry system and exposure conditions logged for every session.
5. Lifetime follow-up and health monitoring: For the subsequent 18–24 months, animals are weighed and clinically assessed on a regular schedule, with periodic blood sampling where the design calls for surveillance of hematologic changes preceding overt disease.
6. Intervention administration (mitigator/protector arms): Candidate radioprotectors, mitigators, or therapeutic agents are administered on the sponsor-defined schedule relative to exposure, with pharmacokinetic and tolerability data collected to interpret leukemogenic outcomes.
7. Moribund euthanasia and case work-up: Animals displaying illness are euthanized promptly, and a standardized necropsy collects sternal bone marrow, spleen, and liver for histopathological assessment against the case-defining infiltration criteria, with blood smears and CBC data incorporated.
8. Molecular confirmation and final analysis: Confirmed cases undergo Sfpi1 mutation analysis, chromosome 2 deletion assessment, and cooperating-event profiling, and the full dataset, incidence, latency distributions, survival curves, and molecular annotations, is assembled into the final report.

Fig 2. Radiation-Induced Leukemia Model Construction Workflow.

Case Study-Radiation-Induced Leukemia Model Development

Alfa Cytology has supported radiation-induced leukemia programs addressing medical countermeasure evaluation, low-dose exposure risk modeling, and the preclinical validation of del2- and Sfpi1-centric mechanistic hypotheses, exploiting the CBA/H model's clean background incidence and human-faithful pathology. These long-horizon engagements have delivered incidence and latency datasets analyzed against established dose-response references, histologically confirmed case series, and molecular annotations of deletion and point-mutation events. Prospective partners are welcome to request further information on study architectures and representative outputs under appropriate confidentiality arrangements.

Why Choose Alfa Cytology?

The radiation leukemia model is a marathon with a single starting gun, and Alfa Cytology is equipped to run every meter of it without losing a single record.

• Reference-strain expertise centered on the CBA/H model with validated alternatives across RF, SJL/J, and C3H/He backgrounds.
• Calibrated-irradiator dosimetry with session-level exposure certificates for every cohort.
• Individual-animal lifetime tracking systems built for 18–24 month follow-up horizons.
• Scheduled in-life hematologic surveillance capturing pre-diagnostic disease evolution.
• Standardized organ-infiltration case criteria with histopathological and molecular confirmation.
• Ph.D.-level radiobiology leadership with single-point accountability from irradiation to final analysis.

Contact Us

For a leukemogenesis platform whose single exposure can illuminate two years of downstream biology, Alfa Cytology stands ready to serve as your long-horizon execution partner. Contact us or reach out to our scientific team today to design your radiation-induced leukemia study, and receive a customized quotation aligned with your preclinical objectives.

For research use only. Not intended for any clinical use.